Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Rohto Pharmaceutical Co ( (JP:4527) ) is now available.
Rohto Pharmaceutical has decided, via a subsidiary, to acquire shares in Thailand-based wellness company Thann Oryza Co., Ltd. (THANN), making it a group subsidiary as part of a strategy to accelerate value creation in the well-being domain. THANN, a premium Asia-originated holistic brand known for natural skincare, aromatherapy-based lifestyle products, and integrated spa and wellness services, operates directly managed stores and spa facilities across multiple Asian markets and exports to 14 countries, giving it strong regional recognition in the spa and wellness sector. By bringing THANN into the group, Rohto plans to respect and preserve THANN’s brand philosophy and assets while combining the strengths of both companies to build a new global value creation model, expand growth opportunities, and reinforce its positioning in the premium wellness and holistic lifestyle market.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2980.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd., headquartered in Osaka, is a Japanese healthcare company focused on over-the-counter pharmaceuticals, skincare, and food-related products, with a strategic emphasis on driving global value creation in health and well-being. The group positions “health” as the foundation of its corporate purpose and targets enhanced well-being worldwide under its Comprehensive Management Vision 2030.
Average Trading Volume: 600,383
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen609.2B
Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.